DexCom (NASDAQ:DXCM) Given “Buy” Rating at Truist Financial

Truist Financial reiterated their buy rating on shares of DexCom (NASDAQ:DXCM) in a research report sent to investors on Tuesday morning,Benzinga reports. Truist Financial currently has a $80.00 price target on the medical device company’s stock, down from their prior price target of $82.00.

Other equities research analysts have also issued research reports about the company. TD Cowen lowered their price objective on DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a report on Friday, October 31st. JPMorgan Chase & Co. decreased their price target on DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Friday, October 31st. Evercore started coverage on DexCom in a research report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price objective for the company. Barclays reissued an “underweight” rating and issued a $72.00 target price (up previously from $71.00) on shares of DexCom in a report on Friday. Finally, Royal Bank Of Canada lowered their price target on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average target price of $85.18.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $70.43 on Tuesday. The stock has a fifty day moving average price of $69.20 and a 200 day moving average price of $69.33. DexCom has a 1-year low of $54.11 and a 1-year high of $93.25. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. The company has a market cap of $27.11 billion, a PE ratio of 33.54, a P/E/G ratio of 1.25 and a beta of 1.49.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. DexCom’s quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.45 EPS. Sell-side analysts forecast that DexCom will post 2.03 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Trust Co. of Vermont boosted its position in DexCom by 14.8% during the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after acquiring an additional 145 shares during the last quarter. CVA Family Office LLC lifted its position in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after buying an additional 147 shares during the period. GAMMA Investing LLC boosted its stake in DexCom by 2.5% in the 3rd quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock worth $474,000 after buying an additional 169 shares during the last quarter. IFP Advisors Inc grew its holdings in DexCom by 24.7% in the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after purchasing an additional 178 shares during the period. Finally, Inspire Investing LLC increased its holdings in shares of DexCom by 6.1% during the 3rd quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock worth $211,000 after buying an additional 180 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.